WO1993006228A1 - A new form of liposaccharide binding protein (lbp) - Google Patents

A new form of liposaccharide binding protein (lbp) Download PDF

Info

Publication number
WO1993006228A1
WO1993006228A1 PCT/US1992/008298 US9208298W WO9306228A1 WO 1993006228 A1 WO1993006228 A1 WO 1993006228A1 US 9208298 W US9208298 W US 9208298W WO 9306228 A1 WO9306228 A1 WO 9306228A1
Authority
WO
WIPO (PCT)
Prior art keywords
lbp
protein
dna
amino acid
expression system
Prior art date
Application number
PCT/US1992/008298
Other languages
French (fr)
Inventor
Jeffrey J. Seilhamer
Angelo M. Delegeane
Original Assignee
Incyte Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals, Inc. filed Critical Incyte Pharmaceuticals, Inc.
Priority to JP5506414A priority Critical patent/JPH07502642A/en
Priority to EP92922186A priority patent/EP0605653A4/en
Publication of WO1993006228A1 publication Critical patent/WO1993006228A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the invention relates to medicaments useful in stimulating the immune system. More specifically, the invention concerns a new form of liposaccharide binding protein (LBP) .
  • LBP liposaccharide binding protein
  • LPS lipopolysaccharides
  • a number of proteins have been described in mammals that bind and mediate the effects of polar lipids such as lipopolysaccharides in circulation. Many of these molecules have been isolated and studied in detail and found to be similar in function and structure. It has been suggested that these proteins can be considered as encoded by a gene family with possible common evolutionary origin.
  • One such protein cholesterol ester transfer protein (CETP) binds cholesterol esters and other complex lipids associated with lipoprotein complexes and mediates their transfer between HDL and VLDL.
  • CETP cholesterol ester transfer protein
  • BPI bacteriocidal permeability increasing protein
  • LBP lipopolysaccharide binding protein
  • BPI and LBP show significant homology, and the homology between BPI and LBP is particularly striking. Both BPI and LBP contain a positively charged amino terminal domain of about 25 kd that appears to be responsible for lipid binding and a hydrophobic carboxy terminal domain of about 30 kd which ' may mediate interaction with membranes and/or receptors.
  • LBP- ⁇ The known form of LBP (LBP- ⁇ ) is synthesized in the liver and is present in normal human serum at a concentration of less than 0.5 ⁇ g/ l. The level rises to 50 ⁇ g/ml 24 hrs after induction of an immune response.
  • the known LBP form has a molecular weight of about 60 kd of which about 10 kd represents added glycosyl residues.
  • LBP has been shown to bind the lipid A moiety of LPS, a binding which presumably involves the amino terminal portion of LBP. The lipid A moiety of LPS is considered essential to induce shock.
  • LBP also opsonizes LPS- bearing particles such as intact gram-negative bacteria, mediating attachment of the coated particles to macrophage.
  • LBP plays an important role in an inflammatory response to infection.
  • Schumann et al. disclose the amino acid sequence and encoding cDNA of both human and rabbit LBP.
  • the present invention provides a novel form of LBP (LBP-/3) not previously described.
  • the present invention provides a novel form of LBP useful in activating the immune system.
  • the novel LBP of the invention designated herein LBP- ⁇ , adds to the repertoire of liposaccharide binding proteins known to stimulate the immune system.
  • LBP- ⁇ adds to the repertoire of liposaccharide binding proteins known to stimulate the immune system.
  • the availability of this additional form of LBP permits fine tuning of therapeutic protocols designed to enhance immune function.
  • the invention is directed to the immune-stimulating protein LBP-3 in purified and isolated form.
  • the invention is directed to recombinant materials and methods useful in providing this protein.
  • the invention is directed to methods to stimulate the immune system using the LBP - ⁇ of the invention, to pharmaceutical compositions useful in this method, and to antibodies reactive with LBP-jS.
  • Figure 1 shows a comparison of the amino acid sequence and nucleic acids encoding LBP- ⁇ ; and LBP-/3.
  • Figure 2 shows the amino acid sequence and the cDNA encoding LBP-/S
  • Figure 3 shows the structure of two ai ⁇ plimers used in PCR in the cloning of LBP - ⁇ .
  • Figure 4 shows a comparison of the amino acid sequence at positions 240-250 of rabbit LBP, human BPI, a previously disclosed form of human LBP (LBP-o;) , and human LBP- ⁇ . The numbering shown refers to Figure 1 of Schumann, et al. (supra) .
  • the LBP-/3 of the invention shows enhanced homology to both human BPI and rabbit LBP as compared to human LBP- ⁇ previously disclosed. There are 7 amino acid substitutions in LBP-j ⁇ relative to LBP- ⁇ (see Fig. 1) . In addition and, more significantly, the LBP-/3 of the invention includes an additional 4 amino acids in the carboxy terminal region which correspond to similar residues in human BPI and rabbit LBP. This sequence was not disclosed in Schumann's LBP- ⁇ _. Four additional amino acids could have a profound effect on the molecule's tertiary structure.
  • novel LBP-j3 of the invention can most conveniently be produced using recombinant techniques.
  • the complete amino acid sequence and cDNA encoding this sequence is disclosed herein and is shown in Figure 2.
  • the amino acid sequence shown in Figure 2 shows the precursor protein which is cleaved to obtain the mature form.
  • the first 25 amino acids effect the secretion of the mature form of LBP which has, as its N-terminus, the Ala residue shown at position 26.
  • the numbering system shown in Figure 2 is thus appropriate to the precursor protein; the corresponding positions in the mature protein are obtained by subtracting 25 from the numbers shown.
  • the valine shown at position 266 in Figure 2 is at position 241 in the mature form.
  • LBP-j ⁇ Such minor and understood modifications provide molecules also included within the scope of the invention and are included within the designation "LBP-j ⁇ .”
  • standard derivatization, by glycosylation, phosphorylation, or chemical modification of sidechains, such as by conversion of proline to hydroxyproline may also be included in proteins designated LBP-/3 and within the scope of the invention so long as these modifications do not destroy the immune system stimulating activity of the protein.
  • the cDNA shown in Figure 2 is identical to that retrieved as described in the illustrations below except for the deliberately engineered Clal site at numbered amino acid positions 222-223. This Clal site was added to enable portions of LBP-jS to be spliced into other constructs in cassette form.
  • any DNA encoding the amino acid sequence of LBP-3 can be included in suitable expression systems for production of this protein.
  • the encoding DNA may be prepared by retrieving the native cDNA, optionally providing degenerate modifications thereof, or may be partially or completely synthesized by conventional solid-phase oligonucleotide synthesizing techniques.
  • Construction of DNA of sufficient length to encode the 482 amino acid LBP-jS precursor or 457 amino acid mature protein can be effected by techniques readily available and known in the art.
  • the DNA encoding the LBP-3 of the invention is ligated to control systems which effect the expression of the coding DNA in host cells with which the control sequences are compatible.
  • the choice of control sequences will thus depend on the nature of the production host cell.
  • Techniques for construction of expression systems, transformation of host cells, and culture of the transformed hosts are now well-established procedures.
  • a variety of expression system/recombinant hosts can be used.
  • E ⁇ coli hosts are available and a variety of control sequences including regulatable promoters such as the trp promoter or P L promoter are well established.
  • Eukaryotic systems useful for production of recombinant proteins include yeast, insect cells, mammalian cells, plant cells, and more recently, intact plants and multicellular organisms.
  • the expression systems may be constructed to provide the LBP-/3 of the invention as the mature protein, or the encoding DNA may be ligated to upstream DNA which encodes a peptide sequence that effects the secretion of the LBP - ⁇ from the recombinant host cell (including the native sequence) or provide LBP-j8 as a fusion protein.
  • Such variations in the design of expression systems are also well known in the art.
  • the LBP-j8 of the invention may also be used to provide antibodies useful in immunoassay systems for the detection of LBP-/3 or related proteins.
  • antibodies which recognize epitopes related to the novel portion of the LBP- ⁇ which distinguishes it from the previously-disclosed human LBP are thus useful.
  • Antibodies may be prepared specifically with respect to this epitope by immunization with a peptide fragment including the portion including amino acids 241-245 of the mature form of LBP-j8 (shown as residues 266-270 of the precursor peptide in Figure 2) .
  • Such fragments may be as short as the 5 amino acid sequence shown, or may include additional amino acid residues derived from LBP-0. Shorter peptides may require conjugation to carrier to enhance immunogenicity.
  • the antibodies of the invention are prepared by standard immunization protocols by repeated administra ⁇ tion to suitable mammalian subjects and monitoring antibody titers in the serum.
  • the polyclonal antiserum may be harvested and used per se, or monoclonal antibodies may be prepared from the peripheral blood lymphocytes or spleens of the immunized animals using standard cell immortalization and screening techniques.
  • immunologically reactive fragments of the antibodies can be advantageously used in many assays and other applications in which the antibodies are useful.
  • the LBP-S of the invention is useful in stimulating the immune system, and thus can be formulated into pharmaceutical compositions for therapeutic use.
  • Standard formulations for administration can be found, for example, in Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, PA (latest edition).
  • suitable formulations for injection include, for example, Hank's solution, Ringer's solution, physiological saline, and the like.
  • LBP-S may also be administered by transmucosal or transdermal formulations, generally transmucosal formulations include detergents or other surface active agents and bile salts or fusidic acids to enhance transition of the membrane. Dosage levels required are comparable to the previously disclosed form of LBP although identification of appropriate dosages for a particular subject and condition depend on the mode of administration, the nature of the subject, the severity of the condition, and the judgment of the attending practitione .
  • Figure 1 shows the oligonucleotide sequence of amplimers designed to complement the regions upstream and downstream of the cDNA encoding LBP described by Schumann (1990) (supra) .
  • the oligonucleotides also contained restriction sites Nhel, Clal, and Xhol, both external and internal to the LBP coding regions.
  • the amplimers shown in Figure 3 were used to amplify LBP encoding DNA from a commercially available cDNA preparation derived from human liver RNA. The amplification utilized standard enzyme-mediated PCR techniques.
  • the amplified products were digested with the corresponding restriction enzymes Nhel, Clal and Xhol and isolated by polyacrylamide gel electrophoresis.
  • the digested cDNA fragments were ligated into pMa Neo, a commercially available mammalian expression vector and cloned in EL. coli.
  • DNA from the resulting clones was analyzed by gel electrophoresis and sequenced. The resulting sequence is shown in Figure 2.
  • the sequence was similar to that reported by Schumann et al. (supra) but also contained an additional sequence of 12 nucleotides in the coding region beginning after base 826 of Genbank sequence 35533, and shown in Figure 2 as positions 824-835.

Abstract

A novel form of liposaccharide binding protein (LBP) is disclosed. This protein can be prepared recombinantly and is useful in stimulating the immune system.

Description

A NEW FORM OF LIPOSACCHARIDE BINDING PROTEIN (LBP)
Technical Field
The invention relates to medicaments useful in stimulating the immune system. More specifically, the invention concerns a new form of liposaccharide binding protein (LBP) .
Background Art
The lipopolysaccharides (LPS) are glycoprotein components of gram-negative bacterial cell walls and are an active part of the etiology of infection by these bacteria. LPS is apparently essential for immune response to the bacteria, and also is involved in the acute effects of such infection, such as septic shock. In order to exert its effects, however, LPS evidently binds to a number of indigenous proteins.
A number of proteins have been described in mammals that bind and mediate the effects of polar lipids such as lipopolysaccharides in circulation. Many of these molecules have been isolated and studied in detail and found to be similar in function and structure. It has been suggested that these proteins can be considered as encoded by a gene family with possible common evolutionary origin. One such protein, cholesterol ester transfer protein (CETP) binds cholesterol esters and other complex lipids associated with lipoprotein complexes and mediates their transfer between HDL and VLDL. Another protein, bacteriocidal permeability increasing protein (BPI) was originally isolated as a naturally-occurring host antibacterial agent. It has later been shown that BPI binds LPS released from bacterial cell walls and appears to neutralize many of its biological effects (Marra, J Immunol (1990) 144:662- 666) . A third protein, lipopolysaccharide binding protein (LBP) also binds LPS, but may mediate its biological effects in triggering cytokine release through a direct interaction of the molecular complex with a specific monocytic cell surface receptor. Thus, the complex of LBP and LPS has been proposed to mediate the activation of macrophages and neutrophils and the release of cytokines such as tumor necrosis factor (TNF) , interleukin-1 (IL-1) and interleukin-6 (IL-6) . See, for example, Schumann et al., Science (1990) 242:1429-1431; Wright, Science (1990) 249:1431-1433.
All of CETP, BPI and LBP show significant homology, and the homology between BPI and LBP is particularly striking. Both BPI and LBP contain a positively charged amino terminal domain of about 25 kd that appears to be responsible for lipid binding and a hydrophobic carboxy terminal domain of about 30 kd which' may mediate interaction with membranes and/or receptors.
The known form of LBP (LBP-α) is synthesized in the liver and is present in normal human serum at a concentration of less than 0.5 μg/ l. The level rises to 50 μg/ml 24 hrs after induction of an immune response. The known LBP form has a molecular weight of about 60 kd of which about 10 kd represents added glycosyl residues. LBP has been shown to bind the lipid A moiety of LPS, a binding which presumably involves the amino terminal portion of LBP. The lipid A moiety of LPS is considered essential to induce shock. LBP also opsonizes LPS- bearing particles such as intact gram-negative bacteria, mediating attachment of the coated particles to macrophage. This binding appears to occur via a specific cellular receptor, CD14, which is free to move within the plane of the cell membrane (Wright et al. (supra)). Thus it is clear that LBP plays an important role in an inflammatory response to infection. Schumann et al. (supra) disclose the amino acid sequence and encoding cDNA of both human and rabbit LBP. The present invention provides a novel form of LBP (LBP-/3) not previously described.
Disclosure of the Invention
The present invention provides a novel form of LBP useful in activating the immune system. The novel LBP of the invention, designated herein LBP-β, adds to the repertoire of liposaccharide binding proteins known to stimulate the immune system. The availability of this additional form of LBP permits fine tuning of therapeutic protocols designed to enhance immune function.
Accordingly, in one aspect, the invention is directed to the immune-stimulating protein LBP-3 in purified and isolated form. In other aspects, the invention is directed to recombinant materials and methods useful in providing this protein. In still other aspects, the invention is directed to methods to stimulate the immune system using the LBP -β of the invention, to pharmaceutical compositions useful in this method, and to antibodies reactive with LBP-jS.
Brief Description of the Drawings
Figure 1 shows a comparison of the amino acid sequence and nucleic acids encoding LBP-α; and LBP-/3.
Figure 2 shows the amino acid sequence and the cDNA encoding LBP-/S,
Figure 3 shows the structure of two aiπplimers used in PCR in the cloning of LBP -β . Figure 4 shows a comparison of the amino acid sequence at positions 240-250 of rabbit LBP, human BPI, a previously disclosed form of human LBP (LBP-o;) , and human LBP-β. The numbering shown refers to Figure 1 of Schumann, et al. (supra) .
Modes of Carrying- Out the Invention
The LBP-/3 of the invention shows enhanced homology to both human BPI and rabbit LBP as compared to human LBP-α previously disclosed. There are 7 amino acid substitutions in LBP-jδ relative to LBP-α (see Fig. 1) . In addition and, more significantly, the LBP-/3 of the invention includes an additional 4 amino acids in the carboxy terminal region which correspond to similar residues in human BPI and rabbit LBP. This sequence was not disclosed in Schumann's LBP-α_. Four additional amino acids could have a profound effect on the molecule's tertiary structure.
This additional quartet of amino acids, of the sequence Met-Ser-Leu-Pro, corresponds to the Met-Asn-Leu- Pro homologous sequence in rabbit LBP and the Met-Glu- Phe-Pro sequence in human BPI. Thus, the quartet found in LBP -β is unique to this protein. A sequence comparison of the residues at positions 240-250 of human BPI, the previously disclosed human LBP, rabbit LBP, and the LBP-/3 of the invention is shown in Figure 4.
The novel LBP-j3 of the invention can most conveniently be produced using recombinant techniques. The complete amino acid sequence and cDNA encoding this sequence is disclosed herein and is shown in Figure 2.
The amino acid sequence shown in Figure 2 shows the precursor protein which is cleaved to obtain the mature form. The first 25 amino acids (positions 1-25) effect the secretion of the mature form of LBP which has, as its N-terminus, the Ala residue shown at position 26. The numbering system shown in Figure 2 is thus appropriate to the precursor protein; the corresponding positions in the mature protein are obtained by subtracting 25 from the numbers shown. Thus, for example, the valine shown at position 266 in Figure 2 is at position 241 in the mature form.
While the invention has reference to LBP-3 corresponding to the amino acid sequence shown at positions 26-482 of Figure 2 herein, it is recognized that minor modifications can be made to the sequence while retaining activity. Specifically, one or several amino acids may be deleted from the N-terminus and/or C- terminus without affecting activity, and one or several amino acid substitutions with residues which are considered conservative with respect to the amino acid residue for which substitution is made may be included without affecting activity in a significant manner. Such minor and understood modifications provide molecules also included within the scope of the invention and are included within the designation "LBP-jδ." In addition, standard derivatization, by glycosylation, phosphorylation, or chemical modification of sidechains, such as by conversion of proline to hydroxyproline may also be included in proteins designated LBP-/3 and within the scope of the invention so long as these modifications do not destroy the immune system stimulating activity of the protein.
The cDNA shown in Figure 2 is identical to that retrieved as described in the illustrations below except for the deliberately engineered Clal site at numbered amino acid positions 222-223. This Clal site was added to enable portions of LBP-jS to be spliced into other constructs in cassette form. However, of course, any DNA encoding the amino acid sequence of LBP-3 can be included in suitable expression systems for production of this protein. The encoding DNA may be prepared by retrieving the native cDNA, optionally providing degenerate modifications thereof, or may be partially or completely synthesized by conventional solid-phase oligonucleotide synthesizing techniques. Construction of DNA of sufficient length to encode the 482 amino acid LBP-jS precursor or 457 amino acid mature protein can be effected by techniques readily available and known in the art. The DNA encoding the LBP-3 of the invention is ligated to control systems which effect the expression of the coding DNA in host cells with which the control sequences are compatible. The choice of control sequences will thus depend on the nature of the production host cell. Techniques for construction of expression systems, transformation of host cells, and culture of the transformed hosts are now well-established procedures. A variety of expression system/recombinant hosts can be used. For prokaryotic expression, conventionally, E^ coli hosts are available and a variety of control sequences including regulatable promoters such as the trp promoter or PL promoter are well established. Eukaryotic systems useful for production of recombinant proteins include yeast, insect cells, mammalian cells, plant cells, and more recently, intact plants and multicellular organisms. The expression systems may be constructed to provide the LBP-/3 of the invention as the mature protein, or the encoding DNA may be ligated to upstream DNA which encodes a peptide sequence that effects the secretion of the LBP -β from the recombinant host cell (including the native sequence) or provide LBP-j8 as a fusion protein. Such variations in the design of expression systems are also well known in the art.
The LBP-j8 of the invention may also be used to provide antibodies useful in immunoassay systems for the detection of LBP-/3 or related proteins. In particular, antibodies which recognize epitopes related to the novel portion of the LBP-β which distinguishes it from the previously-disclosed human LBP are thus useful. Antibodies may be prepared specifically with respect to this epitope by immunization with a peptide fragment including the portion including amino acids 241-245 of the mature form of LBP-j8 (shown as residues 266-270 of the precursor peptide in Figure 2) . Such fragments may be as short as the 5 amino acid sequence shown, or may include additional amino acid residues derived from LBP-0. Shorter peptides may require conjugation to carrier to enhance immunogenicity.
The antibodies of the invention are prepared by standard immunization protocols by repeated administra¬ tion to suitable mammalian subjects and monitoring antibody titers in the serum. The polyclonal antiserum may be harvested and used per se, or monoclonal antibodies may be prepared from the peripheral blood lymphocytes or spleens of the immunized animals using standard cell immortalization and screening techniques. As is well known, immunologically reactive fragments of the antibodies can be advantageously used in many assays and other applications in which the antibodies are useful.
The LBP-S of the invention is useful in stimulating the immune system, and thus can be formulated into pharmaceutical compositions for therapeutic use. Standard formulations for administration can be found, for example, in Remington's Pharmaceutical Sciences. Mack Publishing Co., Easton, PA (latest edition). For administration of proteins such as LBP-3, administration by injection is generally preferred; and suitable formulations for injection include, for example, Hank's solution, Ringer's solution, physiological saline, and the like. LBP-S may also be administered by transmucosal or transdermal formulations, generally transmucosal formulations include detergents or other surface active agents and bile salts or fusidic acids to enhance transition of the membrane. Dosage levels required are comparable to the previously disclosed form of LBP although identification of appropriate dosages for a particular subject and condition depend on the mode of administration, the nature of the subject, the severity of the condition, and the judgment of the attending practitione .
The following examples are included to illustrate but not to limit the invention.
Example 1
Retrieval of cDNA Encoding LBP-β Figure 1 shows the oligonucleotide sequence of amplimers designed to complement the regions upstream and downstream of the cDNA encoding LBP described by Schumann (1990) (supra) . As shown in Figure 3, the oligonucleotides also contained restriction sites Nhel, Clal, and Xhol, both external and internal to the LBP coding regions. The amplimers shown in Figure 3 were used to amplify LBP encoding DNA from a commercially available cDNA preparation derived from human liver RNA. The amplification utilized standard enzyme-mediated PCR techniques.
The amplified products were digested with the corresponding restriction enzymes Nhel, Clal and Xhol and isolated by polyacrylamide gel electrophoresis. The digested cDNA fragments were ligated into pMa Neo, a commercially available mammalian expression vector and cloned in EL. coli. DNA from the resulting clones was analyzed by gel electrophoresis and sequenced. The resulting sequence is shown in Figure 2. The sequence was similar to that reported by Schumann et al. (supra) but also contained an additional sequence of 12 nucleotides in the coding region beginning after base 826 of Genbank sequence 35533, and shown in Figure 2 as positions 824-835.

Claims

Clai s
1. A protein in purified and isolated form which protein comprises the amino acid sequence of mature LBP-/3 shown in positions 26-482 of Figure 2.
2. A recombinant DNA in purified and isolated form which encodes the protein of claim 1.
3. A recombinant expression system capable of expressing the DNA of claim 2, which expression system comprises a DNA encoding said protein operably linked to control sequences heterologous to said encoding DNA.
4. The expression system of claim -3 which is contained in a plasmid.
5. A recombinant host cell transformed with the expression system of claim 3.
6. A method to produce the protein of claim 1, which method comprises culturing the cells of claim 5 under conditions which permit expression of said encoding DNA; and recovering the LBP-J protein from the culture.
7. A pharmaceutical composition which composition contains, as active ingredient, the protein of claim 1 in admixture with a pharmaceutically acceptable excipient.
8. A method for stimulating the immune system in a subject which comprises administering to the subject in need of such stimulation an effective amount of a protein comprising the amino acid sequence of mature LBP- jS shown in positions 25-82 of Figure 2 or a pharmaceutical composition thereof.
9. Antibodies or immunologically reactive fragments thereof specifically reactive with LBP-/3.
PCT/US1992/008298 1991-09-26 1992-09-28 A new form of liposaccharide binding protein (lbp) WO1993006228A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5506414A JPH07502642A (en) 1991-09-26 1992-09-28 A novel form of liposaccharide binding protein (LBP)
EP92922186A EP0605653A4 (en) 1991-09-26 1992-09-28 A new form of liposaccharide binding protein (lbp).

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76566091A 1991-09-26 1991-09-26
US765,660 1991-09-26

Publications (1)

Publication Number Publication Date
WO1993006228A1 true WO1993006228A1 (en) 1993-04-01

Family

ID=25074151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/008298 WO1993006228A1 (en) 1991-09-26 1992-09-28 A new form of liposaccharide binding protein (lbp)

Country Status (4)

Country Link
EP (1) EP0605653A4 (en)
JP (1) JPH07502642A (en)
AU (1) AU2872792A (en)
WO (1) WO1993006228A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
WO1995034289A1 (en) * 1994-06-14 1995-12-21 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US5523288A (en) * 1993-09-22 1996-06-04 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
US5578572A (en) * 1994-01-14 1996-11-26 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
EP0760849A4 (en) * 1993-04-30 1996-12-02 Incyte Pharma Inc Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US5696090A (en) * 1993-02-02 1997-12-09 Xoma Corporation Pharmaceutical composition
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5756464A (en) * 1996-05-23 1998-05-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US5821064A (en) * 1993-09-22 1998-10-13 Xoma Corporation Method of screening for an active inflammatory state by determining the concentration of extracellular BPI
US5856438A (en) * 1993-03-12 1999-01-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US5888977A (en) * 1996-05-10 1999-03-30 Giroir; Brett P. Therapeutic uses of BPI protein products for human meningococcemia
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6051553A (en) * 1993-07-14 2000-04-18 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Jour. Biol. Chem., Vol. 263, No. 27, issued 25 September 1988, P.S. TOBIAS et al., "A family of lipopolysaccharide binding proteins involved in responses to gram-negative sepsis", pages 13479-13481, see entire document. *
Jour. Biol. Chem., Volume 262, No. 31, issued 05 November 1987, C.E. OOI et al., "A 25 KDA NH2-terminal fragment carries all the antibacterial activities of human neutrophil 60-KDA bactericidal/permeability-increasing protein", pages 14891-14894, see entire document. *
Jour. Biol. Chem., Volume 264, No. 18, issued 25 June 1989, P.S. TOBIAS et al., "Identification of a lipid a binding site in the acute phase reactant lipopolysaccharide binding protein", pages 10867-10871, see entire document. *
Jour. Immunol., Volume 144, No. 2, issued 15 January 1990, M.N. MARRA et al., "Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity", pages 662-666, see entire document. *
Res. Immunol., Volume 143, issued January 1992, R.R. SCHUMANN, "Function of lipopolysaccharide(LPS)-binding protein (LBP) and CD14, the receptor for LPS/LBP complexes: a short review", see entire document. *
Science, Volume 249, issued 21 September 1990, R.R. SCHUMANN et al., "Structure and function of lipopolysaccharide binding protein", pages 1429-1431. *
Science, Volume 249, issued 21 September 1990, S.D. WRIGHT et al., "CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein", pages 1431-1433, see entire document. *
See also references of EP0605653A4 *

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265187B1 (en) 1989-02-14 2001-07-24 Incyte Pharmaceuticals, Inc. Recombinant endotoxin-neutralizing proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US6433140B1 (en) 1993-02-02 2002-08-13 Xoma Corporation Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same
US6066620A (en) * 1993-02-02 2000-05-23 Xoma Corporation Pharmaceutical compositions of bactericidal/permeability increasing protein (BPI)
US6828418B2 (en) 1993-02-02 2004-12-07 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
US5827816A (en) * 1993-02-02 1998-10-27 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
US5955427A (en) * 1993-02-02 1999-09-21 Xoma Corporation Pharmaceutical composition
US6255284B1 (en) 1993-02-02 2001-07-03 Xoma Corporation Pharmaceutical composition
US5696090A (en) * 1993-02-02 1997-12-09 Xoma Corporation Pharmaceutical composition
US5674834A (en) * 1993-02-02 1997-10-07 Xoma Corporation Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions containing the same
US6214789B1 (en) 1993-03-12 2001-04-10 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US6620785B2 (en) 1993-03-12 2003-09-16 Xoma Corporation Treatment of Mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5856438A (en) * 1993-03-12 1999-01-05 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EP0760849A1 (en) * 1993-04-30 1997-03-12 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
EP0760849A4 (en) * 1993-04-30 1996-12-02 Incyte Pharma Inc Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
US6376462B1 (en) 1993-06-17 2002-04-23 Xoma Corporation Lipopolysaccharide binding protein derivatives
US5770561A (en) * 1993-07-14 1998-06-23 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6051553A (en) * 1993-07-14 2000-04-18 Xoma Corporation Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US5821064A (en) * 1993-09-22 1998-10-13 Xoma Corporation Method of screening for an active inflammatory state by determining the concentration of extracellular BPI
US6140306A (en) * 1993-09-22 2000-10-31 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
US6759203B1 (en) 1993-09-22 2004-07-06 Xoma Corporation Method for quantifying BPI in body fluids
US5523288A (en) * 1993-09-22 1996-06-04 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (BPI) protein product and antibiotic
US5627153A (en) * 1994-01-14 1997-05-06 Xoma Corporation Anti-fungal methods and materials
US5783561A (en) * 1994-01-14 1998-07-21 Xoma Corporation Anti-gram-positive bacterial methods and materials
US6054431A (en) * 1994-01-14 2000-04-25 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5578572A (en) * 1994-01-14 1996-11-26 Xoma Corporation Anti-gram-positive bacterial methods and materials
US5891618A (en) * 1994-01-24 1999-04-06 Xoma Corporation Method for quantifying LBP in body fluids
US6274328B1 (en) 1994-01-24 2001-08-14 Xoma Corporation Method for quantifying LBP in body fluids
US5990086A (en) * 1994-01-24 1999-11-23 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US5804367A (en) * 1994-01-24 1998-09-08 Xoma Corporation Method for quantifying LBP in body fluids
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US7081334B2 (en) 1994-01-24 2006-07-25 Xoma Corporation Method for quantifying LBP in body fluids
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US6767893B2 (en) 1994-04-22 2004-07-27 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US6017881A (en) * 1994-04-22 2000-01-25 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US6268345B1 (en) 1994-05-31 2001-07-31 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5932544A (en) * 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US6057293A (en) * 1994-05-31 2000-05-02 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
WO1995034289A1 (en) * 1994-06-14 1995-12-21 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5928624A (en) * 1994-06-14 1999-07-27 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US5932536A (en) * 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
US6271203B1 (en) 1994-07-07 2001-08-07 Xoma Corporation Anti-protozoan methods and materials
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
US6440936B2 (en) 1994-07-11 2002-08-27 Xoma Corporation Anti-protozoan methods and materials
US6013629A (en) * 1994-07-11 2000-01-11 Xoma Corporation Anti-protozoan methods and materials
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
US6242418B1 (en) 1996-05-10 2001-06-05 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US6596691B2 (en) 1996-05-10 2003-07-22 Xoma Corporation Therapeutic uses of BPI protein products for human meningococcemia
US5888977A (en) * 1996-05-10 1999-03-30 Giroir; Brett P. Therapeutic uses of BPI protein products for human meningococcemia
US5945399A (en) * 1996-05-23 1999-08-31 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma
US5756464A (en) * 1996-05-23 1998-05-26 Xoma Corporation Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma
US6583116B1 (en) 1996-08-09 2003-06-24 Xoma Corporation Anti-chlamydial methods and materials
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6162788A (en) * 1996-08-09 2000-12-19 Xoma Corporation Uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6306824B1 (en) 1997-10-22 2001-10-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US5990082A (en) * 1997-10-22 1999-11-23 Xoma Corporation Uses of lipopolysaccharide binding protein
US6599880B1 (en) 1998-06-19 2003-07-29 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6087126A (en) * 1998-06-19 2000-07-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides

Also Published As

Publication number Publication date
JPH07502642A (en) 1995-03-23
EP0605653A1 (en) 1994-07-13
AU2872792A (en) 1993-04-27
EP0605653A4 (en) 1995-03-15

Similar Documents

Publication Publication Date Title
WO1993006228A1 (en) A new form of liposaccharide binding protein (lbp)
US11008374B2 (en) Uses of IL-15 antagonists for the treatment of autoimmune and inflammatory diseases
EP0752886B1 (en) Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes
US7959925B2 (en) Trimeric OX40-immunoglobulin fusion protein and methods of use
JP2804237B2 (en) DNA encoding recombinant lymphotoxin
US7101689B2 (en) Interleukin-18 binding proteins, their preparation and use
EP0975668B1 (en) MODIFIED TNFalpha MOLECULES, DNA ENCODING SUCH MODIFIED TNFalpha MOLECULES AND VACCINES COMPRISING SUCH MODIFIED TNFalpha MOLECULES AND DNA
KR100393508B1 (en) New hIL-4 Mutant Proteins as Antagonists or Partial Agonists of Human Interleukin 4
CA2628546A1 (en) Therapeutic vaccines targeting hmgb1
AU758576B2 (en) Chemokines with amino-terminal modifications
JPH11514861A (en) Chemokine inhibitor
US7285273B1 (en) Method for down-regulating IL5 activity
AU2013263717B2 (en) Trimeric OX40L-immunoglobulin fusion protein and methods of use
EP1448598A2 (en) Novel immunogenic mimetics of multimer proteins
ZA200403686B (en) Immunogenic mimetics of multimer proteins with promiscuous T cell epitope inserts
EP1781684A2 (en) A novel chimeric polypeptide and use thereof
CA2272051A1 (en) Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation
JP2000511418A (en) Human interleukin-1j and its antagonist
US20060222624A1 (en) Detoxified TNF and method of preparing
CN1366049A (en) Chinese bee venom AcHA gene, polypeptide coded by it and its preparing process
JP3022950B2 (en) B cell differentiation factor
ZA200102131B (en) Method for down-regulating osteoprotegerin ligand activity.
CN1290749A (en) Charcot-leyden crystal IB and its coding sequence and producing method and use
JP2002504823A (en) Human L105 protein and polynucleotide encoding the same
AU2002342596A1 (en) Immunogenic mimetics of multimer proteins with promiscuous T cell epitope inserts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1992922186

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992922186

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1992922186

Country of ref document: EP